Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$31.11B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.44 | 2.39%
Avg Daily Range (30 D):	$8.21 | 2.08%
Avg Daily Range (90 D):	$11.20 | 2.42%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	1.02M
Avg Daily Volume (90 D):	.95M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	22
Avg Trade Size (Sh.) (90 D):	22

Institutional Trades
Total Institutional Trades:	3,669
Avg Institutional Trade:	$17M
Avg Institutional Trade (30 D):	$24.94M
Avg Institutional Trade (90 D):	$28.52M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$30.12M
Avg Closing Trade (30 D):	$52.85M
Avg Closing Trade (90 D):	$56.67M
Avg Closing Volume:	88.72K

News

May 18, 2026 @ 1:30 PM I'm Buying the Stocks Everyone Else Is Selling Rig... Source: Neil Rozenbaum

May 14, 2026 @ 2:30 PM Axon Surged After Earnings and Is Still Down Over ... Source: Leo Miller

May 6, 2026 @ 8:49 PM Axon Shares Slip Despite Q1 Results Above Expectat... Source: Erica Kollmann

Apr 30, 2026 @ 7:35 AM 2 Factors Dragging Down Axon Enterprise Stock: Sho... Source: Thomas Niel

Apr 23, 2026 @ 8:24 AM This AI Stock Is Up 2,000% in 10 Years. It Could S... Source: Trevor Jennewine

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.11	$.03	$1.6
Diluted EPS	$2.05	$.03	$1.51
Revenue	$807.35M	$796.72M	$2.78B
Gross Profit	$477.29M	$461.3M	$1.66B
Net Income / Loss	$169.31M	$2.75M	$124.66M
Operating Income / Loss	$29.24M	$-50.12M	$-62.08M
Cost of Revenue	$330.06M	$335.43M	$1.12B
Net Cash Flow	$-742.24M	$-222.75M	$746.63M
PE Ratio

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1